Depression & Insulin Sensitivity in Adolescents
Primary Purpose
Type2 Diabetes, Type 2 Diabetes Mellitus, Insulin Sensitivity
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Cognitive-behavioral therapy group
Health education group
Sponsored by
About this trial
This is an interventional prevention trial for Type2 Diabetes
Eligibility Criteria
Inclusion Criteria:
- Female
- Age 12-17 years
- Body mass index (BMI) ≥85th percentile for age & sex
- Center for Epidemiologic Studies-Depression Scale (CES-D) >20
- English speaking
- ≥1 first- or second-degree family member with type 2 diabetes (T2D), prediabetes, or gestational diabetes
- Good general health
Exclusion Criteria:
- Pregnancy or breastfeeding
- Type 2 diabetes as indicated by fasting glucose≥126 mg/dL or 2-hour glucose>200 mg/dL or Hba1c>=6.5
- Medication affecting mood, weight, cortisol, or insulin sensitivity, including insulin sensitizers (e.g., metformin), anti-depressants, and stimulants
- Major psychiatric disorder that, in the opinion of the investigators, would impede study compliance and necessitate more intensive treatment, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, panic disorder, obsessive-compulsive disorder, schizophrenia, conduct disorder, alcohol and substance abuse, and anorexia/bulimia nervosa
- Psychotherapy or structured weight loss program
- Active suicidal ideation or suicidal behavior
Sites / Locations
- Children's Hospital ColoradoRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Cognitive-behavioral therapy group
Health education group
Arm Description
Six-session cognitive-behavioral therapy group program designed as a prevention of depression intervention for adolescents at-risk for depression. The program is facilitated by a psychologist. Sessions are weekly for 1-hour.
Six-session health education group program designed as a health education curriculum for teenagers. The program is facilitated by a psychologist. Sessions are weekly for 1-hour.
Outcomes
Primary Outcome Measures
Depressive symptoms
Center for Epidemiologic Studies-Depression Scale (CES-D) total score
Insulin sensitivity
Whole body insulin sensitivity index estimated from 2-hour oral glucose tolerance test
Insulin secretion
Oral disposition index estimated from 2-hour oral glucose tolerance test
Secondary Outcome Measures
Disinhibited eating
Emotional Eating Scale adapted for Children depression scale
Physical activity
Moderate-to-vigorous physical activity by accelerometer
Physical inactivity
Sedentary time by accelerometer
Sleep
Sleep duration by actigraphy
Cortisol diurnal rhythm
Salivary cortisol by home collection throughout the day
Daily cortisol output
24-hour urine cortisol
Full Information
NCT ID
NCT03263351
First Posted
August 24, 2017
Last Updated
July 28, 2023
Sponsor
Colorado State University
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Advancing Translational Sciences (NCATS), Children's Hospital Colorado, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1. Study Identification
Unique Protocol Identification Number
NCT03263351
Brief Title
Depression & Insulin Sensitivity in Adolescents
Official Title
Depression and Insulin Sensitivity in Adolescents
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 1, 2017 (Actual)
Primary Completion Date
October 31, 2023 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Colorado State University
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Advancing Translational Sciences (NCATS), Children's Hospital Colorado, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
There has been a rise in type 2 diabetes (T2D) rates in adolescents, disproportionately in girls from disadvantaged racial/ethnic groups. This group of girls also is at heightened risk for depression, and depression and T2D are linked. Depressive symptoms are a risk factor for worsening of insulin sensitivity, one if the major precursors to T2D. In preliminary studies, the investigators found that a brief cognitive-behavioral therapy group decreased depressive symptoms and prevented worsening of insulin sensitivity in adolescent girls at-risk for T2D with moderate depressive symptoms. The aims of this study are: 1) to assess the efficacy of a cognitive-behavioral therapy depression group vs. a health education control group for improving insulin sensitivity and preserving insulin secretion in racially/ethnically diverse adolescent girls at-risk for T2D with moderate depressive symptoms over a 1-year follow-up; 2) to evaluate changes in eating, physical activity, and sleep as explanatory and 3) to test changes in cortisol factors as explanatory.
Detailed Description
There has been rapid escalation of type 2 diabetes (T2D) rates in adolescents. Early-onset T2D (<20y) typically shows a more aggressive course than adult-onset T2D and disproportionately affects girls from disadvantaged, racial/ethnic groups. This group of girls also is at heightened risk for depression, and depression and T2D are linked. Depressive symptoms often manifest in adolescence and are a prospective risk factor for worsening of insulin sensitivity, the major physiological precursor-in combination with deterioration of pancreatic β-cell capacity to secrete insulin-in the path to T2D. The effects of depression on poor insulin sensitivity remain even after accounting for adiposity. In theory, depressive symptoms may worsen insulin sensitivity through stress-induced behaviors (e.g., disinhibited eating, physical inactivity, sleep disturbance) and stress-induced physiological causal mechanisms (e.g., hypercortisolism). The central theme of this study is that intervening to reduce depressive symptoms in adolescents at-risk for T2D may offer an innovative, targeted approach to ameliorate insulin resistance and to, consequently, preserve β-cell function and lessen T2D risk. In preliminary data, the investigators found initial evidence that a 6-week cognitive-behavioral group decreased depressive symptoms and prevented worsening of insulin sensitivity 1 year later in overweight and obese girls with moderate depressive symptoms and a family history of T2D, in comparison to a 6-week health education control group. Directly extending these findings, the primary aims of this study are: 1) to assess the efficacy of a 6-week cognitive-behavioral depression group vs. a 6-week health education control group for improving insulin sensitivity and preserving β-cell function in racially/ethnically diverse adolescent girls at-risk for T2D with moderate depressive symptoms over a 1-year follow-up; 2) to evaluate changes in eating, physical activity, and sleep as behavioral explanatory mediators underlying the relationship between decreases in depressive symptoms and improvements in insulin sensitivity and β-cell function over 1 year and 3) to test changes in cortisol awakening response, diurnal cortisol rhythm, and total daily cortisol output as physiological mechanisms explaining the relationship between decreases in depressive symptoms and improvements in insulin sensitivity and β-cell function over 1 year.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type2 Diabetes, Type 2 Diabetes Mellitus, Insulin Sensitivity, Insulin Resistance, Depression, Adolescent Obesity
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This is a randomized controlled behavioral trial with two conditions - cognitive-behavioral therapy group or health education group - run in parallel.
Masking
Outcomes Assessor
Masking Description
Research staff who assess outcomes will be blinded to condition assignment.
Allocation
Randomized
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Cognitive-behavioral therapy group
Arm Type
Experimental
Arm Description
Six-session cognitive-behavioral therapy group program designed as a prevention of depression intervention for adolescents at-risk for depression. The program is facilitated by a psychologist. Sessions are weekly for 1-hour.
Arm Title
Health education group
Arm Type
Active Comparator
Arm Description
Six-session health education group program designed as a health education curriculum for teenagers. The program is facilitated by a psychologist. Sessions are weekly for 1-hour.
Intervention Type
Behavioral
Intervention Name(s)
Cognitive-behavioral therapy group
Other Intervention Name(s)
Blues Program
Intervention Description
Psychoeducation on depression; cognitive restructuring of negative thoughts; engagement in pleasant activities; healthy rewards; stress and coping.
Intervention Type
Behavioral
Intervention Name(s)
Health education group
Other Intervention Name(s)
Hey-Durham
Intervention Description
Didactic health knowledge about interpersonal violence; basic nutrition guidance; sun safety; depression and signs of suicide; gang violence; substance use.
Primary Outcome Measure Information:
Title
Depressive symptoms
Description
Center for Epidemiologic Studies-Depression Scale (CES-D) total score
Time Frame
1-year
Title
Insulin sensitivity
Description
Whole body insulin sensitivity index estimated from 2-hour oral glucose tolerance test
Time Frame
1-year
Title
Insulin secretion
Description
Oral disposition index estimated from 2-hour oral glucose tolerance test
Time Frame
1-year
Secondary Outcome Measure Information:
Title
Disinhibited eating
Description
Emotional Eating Scale adapted for Children depression scale
Time Frame
1-year
Title
Physical activity
Description
Moderate-to-vigorous physical activity by accelerometer
Time Frame
1-year
Title
Physical inactivity
Description
Sedentary time by accelerometer
Time Frame
1-year
Title
Sleep
Description
Sleep duration by actigraphy
Time Frame
1-year
Title
Cortisol diurnal rhythm
Description
Salivary cortisol by home collection throughout the day
Time Frame
1-year
Title
Daily cortisol output
Description
24-hour urine cortisol
Time Frame
1-year
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female
Age 12-17 years
Body mass index (BMI) ≥85th percentile for age & sex
Center for Epidemiologic Studies-Depression Scale (CES-D) >20
English speaking
≥1 first- or second-degree family member with type 2 diabetes (T2D), prediabetes, or gestational diabetes
Good general health
Exclusion Criteria:
Pregnancy or breastfeeding
Type 2 diabetes as indicated by fasting glucose≥126 mg/dL or 2-hour glucose>200 mg/dL or Hba1c>=6.5
Medication affecting mood, weight, cortisol, or insulin sensitivity, including insulin sensitizers (e.g., metformin), anti-depressants, and stimulants
Major psychiatric disorder that, in the opinion of the investigators, would impede study compliance and necessitate more intensive treatment, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, panic disorder, obsessive-compulsive disorder, schizophrenia, conduct disorder, alcohol and substance abuse, and anorexia/bulimia nervosa
Psychotherapy or structured weight loss program
Active suicidal ideation or suicidal behavior
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lauren B Shomaker, PhD
Phone
(970)491-3217
Email
lauren.shomaker@colostate.edu
Facility Information:
Facility Name
Children's Hospital Colorado
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lauren Shomaker, PhD
Phone
720-777-3138
Email
lauren.shomaker@childrenscolorado.org
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
2733389
Citation
Andrews SA, Colvin HJ. Verification of Intoximeter 3000 breath alcohol concentration by magnesium perchlorate tube method in long-term field program. J Anal Toxicol. 1989 Mar-Apr;13(2):113-6. doi: 10.1093/jat/13.2.113.
Results Reference
background
PubMed Identifier
28370947
Citation
Shomaker LB, Kelly NR, Radin RM, Cassidy OL, Shank LM, Brady SM, Demidowich AP, Olsen CH, Chen KY, Stice E, Tanofsky-Kraff M, Yanovski JA. Prevention of insulin resistance in adolescents at risk for type 2 diabetes with depressive symptoms: 1-year follow-up of a randomized trial. Depress Anxiety. 2017 Oct;34(10):866-876. doi: 10.1002/da.22617. Epub 2017 Mar 31.
Results Reference
background
Learn more about this trial
Depression & Insulin Sensitivity in Adolescents
We'll reach out to this number within 24 hrs